Chemily, LLC is organized around cost-effective synthesis of glycan libraries, carbohydrate-based biochemicals, reagents and pharmaceuticals. With the objective of becoming a major supplier for carbohydrate-based biochemicals, reagents and pharmaceuticals the firm has been manufacturing several categories of products using its proprietary chemo-enzymatic and in vivo bioengineering technology. New developments include: Structure-defined oligosaccharides and glycolipids;.Immunogenic bacterial cell surface polysaccharides; Sugar nucleotides and their derivatives; Carbohydrate-based pharmaceuticals and glycoprotein vaccines; Carbohydrate related enzymes, such as glycosyl transferases, glycosyl hydrolases, sugar nucleotide biosynthesized enzymes. Based on its proprietary carbohydrate and uncommon sugar library (deposits), CHEMILY has been developing sugar-containing small molecules in therapeutic treatment options in two core disease areas: cancer and cardiovascular diseases. Recently, CHEMILY has come back into the SBIR space after a few year absence and has been licensing and developing novel glycoconjugation technology to produce polysaccharide-protein conjugate vaccines and therapeutic glycoproteins to unprecedented cost effective levels.
